Treatment of chronic viral hepatitis C with direct acting antiviral agent: review


Cite item

Full Text

Abstract

HCV infection treatment regimens are viewed from positions of HCV life cycle and replication, effects of NS3/4A protease inhibitors and NS5A/NS5B inhibitors on HCV strain replication. Evolution of HCV treatment regimens from its discovery to modern DAA agents had led to substantial progress although drug resistance poses a new issue to be addressed.

About the authors

V A Malov

Sechenov First Moscow State Medical University

д.м.н., проф., проф. каф. инфекционных болезней МПФ ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет), ORCID: 0000-0002-6157-1654 Moscow, Russia

E A Ubeeva

Dorgi Banzarov Buryat State University

аспирант каф. фармакологии ФБГОУ ВО «Бурятский государственный университет им. Доржи Банзарова»; ORCID: 0000-0002-9835-2279 Ulan-Ude, Russia

I P Ubeeva

Dorgi Banzarov Buryat State University

д.м.н., проф., проф. каф. инфекционных болезней ФБГОУ ВО «Бурятский государственный университет им. Доржи Банзарова», ORCID: 0000-0001-8206-8436 Ulan-Ude, Russia

S M Nikolaev

Dorgi Banzarov Buryat State University

д.м.н., проф., проф. каф. фармакологии ФБГОУ ВО «Бурятский государственный университет им. Доржи Банзарова», ORCID: 0000-0002-5833-7576 Ulan-Ude, Russia

K T Umbetova

Sechenov First Moscow State Medical University

д.м.н., проф. каф. инфекционных болезней МПФ ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет), ORCID: 0000-0002-0902-9267 Moscow, Russia

References

  1. Климова Е.А. Гепатит С. В кн.: Инфекционные болезни: национальное руководство. Под ред. Ющука Н.Д., Венгерова Ю.Я. М.: ГЭОТАР-Медиа, 2018:688-702.
  2. Пименов Н.Н., Комарова С.В., Карандашова И.В., Цапкова Н.А., Волчкова Е.В., Чуланов В.П. Гепатит C и его исходы в России: анализ заболеваемости, распространенности и смертности до начала программы элиминации инфекции. Инфекционные болезни. 2018;16(3):37-45. doi: 10.20953/1729-2018-3-37-45
  3. Kwo P.Y, Poordad F, Asatryan A, Wang S, Wyles D.L, Hassanein T, Felizarta F, Sulkowski M.S, Gane E, Maliakkal B, Overcash J.S, Gordon S.C, Muir A.J, Aguilar H, Agarwal K, Dore G.J, Lin C.W, Liu R, Lovell S.S, Ng T.I, Kort J, Mensa F.J. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263-71. doi: 10.1016/j.jh ep.2017.03.039
  4. Baatarkhuu O, Kim D.Y, Ahn S.H, Nymadawa P, Dahgwahdorj Y, Shagdarsuren M, Park J.Y, Choi J.W, Oyunbileg J, Oyunsuren T, Han K.H. Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population - based nationwide study. Liver Int. 2008;28(10):1389-95. doi: 10.1111/j.1478-3231.2008.01820.x
  5. Qureshi H, Bile K.M, Jooma R, Alam S.E, Afridi H.U. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J. 2010;16(Suppl):S15-S23.
  6. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-S57. doi: 10.1016/j.jhep.2014.07.027
  7. Spradling P.R, Rupp L, Moorman A.C, Lu M, Teshale E.H, Gordon S.C, Nakasato C, Boscarino J.A, Henkle E.M, Nerenz D.R, Denniston M.M, Holmberg S.D; Chronic Hepatitis Cohort Study Investigators. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55(8):1047-55. doi: 10.1093/cid/cis616
  8. Manns M.P, Buti M, Gane E, Pawlotsky J.M, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. doi: 10.1038/ nrdp.2017.6
  9. European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325-36. doi: 10.1016/S2468-1253(17)30045-6
  10. Alter M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-41. doi: 10.3748/wjg.v13.i17.2436
  11. Рекомендации по диагностике и лечению взрослых больных гепатитом С. Ющук Н.Д. и др. М.:ГЭОТАР-Медиа, 2017.
  12. Stanaway J.D, Flaxman A.D, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad L.J, Assadi R, Bhala N, Cowie B, Forouzanfour M.H, Groeger J, Hanafiah K.M, Jacobsen K.H, James S.L, Mac Lachlan J, Malekzadeh R, Martin N.K, Mokdad A.A, Mokdad A.H, Murray C.J.L, Plass D, Rana S, Rein D.B, Richardus J.H, Sanabria J, Saylan M, Shahraz S, So S, Vlassov V.V, Weiderpass E, Wiersma S.T, Younis M, Yu C, E.l Sayed Zaki M, Cooke G.S. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-8. doi: 10.1016/ S0140-6736(16)30579-7
  13. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon S.C, Schultz M, Davis M.N, Kayali Z, Reddy K.R, Jacobson I.M, Kowdley K.V, Nyberg L, Subramanian G.M, Hyland R.H, Arterburn S, Jiang D, McNally J, Brainard D, Symonds W.T, McHutchison J.G, Sheikh A.M, Younossi Z, Gane E.J. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87. doi: 10.1056/NEJMoa1214853
  14. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modeling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76. doi: 10.1016/S2468-1253(16)30181-9
  15. Reau N, Kwo P.Y, Rhee S, Brown R.S. Jr, Agarwal K, Angus P, Gane E, Kao J.H, Mantry P.S, Mutimer D, Reddy K.R, Tran T.T, Hu Y.B, Gulati A, Krishnan P, Dumas E.O, Porcalla A, Shulman N.S, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018;68(4):1298-307. doi: 10.1002/ hep.30046
  16. Scheel T.K, Rice C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine. 2013;19(7):837-49. doi: 10.1038/nm.3248
  17. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285(5424):110-3.
  18. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette J.C, Opolon P. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum. 1999;42(10): 2204-12.
  19. Thein H.H, Yi Q, Dore G.J, Krahn M.D. Estimation of stage - specific fibrosis progression rates in chronic hepatitis C virus infection: a meta - analysis and meta - regression. Hepatology. 2008;48(2):418-31. doi: 10.1002/hep.22375
  20. Takehara T, Hayashi N, Mita E, Hagiwara H, Ueda K, Katayama K, Kasahara A, Fusamoto H, Kamada T. Detection of the minus strand of hepatitis C virus RNA by reverse transcription and polymerase chain reaction: Implications for hepatitis C virus replication in infected tissue. Hepatology. 1992;15(3):387-90.
  21. Revie D, Salahuddin S.Z. Human cell types important for Hepatitis C Virus replication in vivo and in vitro: old assertions and current evidence. Virol J. 2011;8:346. doi: 10.1186/1743-422X-8-346
  22. Everson G.T, Towner W.J, Davis M.N, Wyles D.L, Nahass R.G, Thuluvath P.J, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, Mc Nally J, Brainard D.M, Han L, Doehle B, Mc Hutchison J.G, Morgan T, Chung R.T, Tran T.T. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015;163(11):818-26. doi: 10.7326/M15-1000
  23. Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects. https://clinicaltrials.gov/ct2/show/ NCT03092375
  24. Owens C.M, Brasher B.B, Polemeropoulos A, Rhodin M.H, Mc Allister N, Wong K.A, Jones C.T, Jiang L, Lin K, Or Y.S. Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor. Antimicrob Agents Chemother. 2016;60(10):6216-26. doi: 10.1128/AAC.00815-16
  25. Forns X, Lee S.S, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson D.R, Yu Y, Krishnan P, Lin C.W, Kort J.J, Mensa F.J. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single - arm, open - label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062-8. doi: 10.1016/ S1473-3099(17)30496-6
  26. Zeuzem S, Foster G.R, Wang S, Asatryan A, Gane E, Feld J.J, Asselah T, Bourlière M, Ruane P.J, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang W.L, Stedman C.A, Flamm S, Kwo P, Dore G.J, Sepulveda-Arzola G, Roberts S.K, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas H.E, Bruck R, Fuster F, Paik S.W, Felizarta F, Kort J, Fu B, Liu R, Ng T.I, Pilot-Matias T, Lin C.W, Trinh R, Mensa F.J. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354-69. doi: 10.1056/ NEJMoa1702417
  27. Kwo P.Y, Poordad F, Asatryan A, Wang S, Wyles D.L, Hassanein T, Felizarta F, Sulkowski M.S, Gane E, Maliakkal B, Overcash J.S, Gordon S.C, Muir A.J, Aguilar H, Agarwal K, Dore G.J, Lin C.W, Liu R, Lovell S.S, Ng T.I, Kort J, Mensa F.J. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263-71. doi: 10.1016/j.jhep.2017.03.039
  28. Wilson E, et al. Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience (RESOLVE). https://clinicaltrials.gov/ct2/show/NCT02745535
  29. Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri M.I, Scuderi L, Malaguarnera G, Bertino N, Rapisarda V, Di Carlo I, Toro A, Salomone F, Malaguarnera M, Bertino E, Malaguarnera M. Chronic hepatitis C: This and the new era of treatment. World J Hepatol. 2016;8(2):92-106. doi: 10.4254/wjh.v8.i2.92
  30. Foster G.R, Afdhal N, Roberts S.K, Bräu N, Gane E.J, Pianko S, Lawitz E, Thompson A, Shiffman M.L, Cooper C, Towner W.J, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman C.A, Mo H, Dvory-Sobol H, Han L, Wang J, Mc Nally J, Osinusi A, Brainard D.M, Mc Hutchison J.G, Mazzotta F, Tran T.T, Gordon S.C, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608-17. doi: 10.1056/NEJMoa1512612
  31. Manns M.P, Cornberg M. Sofosbuvir: the final nail in the coffin for hepatitis C? Lancet Infect Dis. 2013;13(5):378-9. doi: 10.1016/S1473-3099(13)70074-4
  32. Feld J.J, Jacobson I.M, Hézode C, Asselah T, Ruane P.J, Gruener N, Abergel A, Mangia A, Lai C.L, Chan H.L, Mazzotta F, Moreno C, Yoshida E, Shafran S.D, Towner W.J, Tran T.T, Mc Nally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard D.M, Mc Hutchison J.G, Agarwal K, Zeuzem S; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599-607. doi: 10.1056/NEJMoa 1512610
  33. El Kassas M, Elbaz T, Abd El Latif Y, Esmat G. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Rev Clin Pharmacol. 2016; 9(11):1413-21. doi: 10.1080/17512433.2016.1233813
  34. Asselah T, Kowdley K.V, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry P.S, Hezode C, Marinho R.T, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng T.I, Krishnan P, Lin C.W, Mensa F.J. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417-26. doi: 10.101 6/j.cgh.2017.09.027
  35. Kliemann D.A, Tovo C.V, da Veiga A.B, de Mattos A.A, Wood C. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol. 2016;22(40):8910-7. doi: 10.3748/wjg.v22.i40.8910
  36. Апросина З.Г. Хронический активный гепатит как системное заболевание. М.: Медицина, 1981.
  37. Chung R.T, et al. Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant. https://clinicaltrials.gov/ct2/show/ NCT03623568
  38. Cacoub P, Commarmond C, Sadoun D, Desbois A.C. Hepatitis C virus infection and rheumatic diseases: the impact of direct - acting antiviral agents. Rheum Dis Clin North Am. 2017;43(1):123-32. doi: 10.1016/j.rdc.2016.09.011
  39. Negro F, Forton D, Craxi A, Sulkowski M.S, Feld J.J, Manns M.P. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6):1345-60. doi: 10.1053/j.gastro.2015.08.035

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies